Salvage Second Hematopoietic Cell Transplantation in Myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 5, 2013, Pages 760-766

  Michaelis, Laura C ^a   Saad, Ayman ^b   Zhong, Xiaobo ^c   Le Rademacher, Jennifer ^c   Freytes, Cesar O ^d   Marks, David I ^e   Lazarus, Hillard M ^f   Bird, Jennifer M ^e   Holmberg, Leona ^g   Kamble, Rammurti T ^h   Kumar, Shaji ⁱ   Lill, Michael ^j   Meehan, Kenneth R ^k   Saber, Wael ^c   Schriber, Jeffrey ^l   Tay, Jason ^m   Vogl, Dan T ⁿ   Wirk, Baldeep ^o   Savani, Bipin N ^p   Gale, Robert P ^q   Vesole, David H ^r   Schiller, Gary J ^s   Abidi, Muneer ^t   Anderson, Kenneth C ^u   Nishihori, Taiga ^v   Kalaycio, Matt E ^w   Vose, Julie M ^x   Moreb, Jan S ^o   Drobyski, William ^y   Munker, Reinhold ^z   Roy, Vivek ^aa   Ghobadi, Armin ^ab   Holland, H Kent ^ac   Nath, Rajneesh ^ad   To, L Bik ^ae   Maiolino, Angelo ^af   Kassim, Adetola A ^p   Giralt, Sergio A ^ag   Landau, Heather ^ag   Schouten, Harry C ^ah   Maziarz, Richard T ^ai   Michael, Joseph ^aj   Kindwall Keller, Tamila ^ak   Stiff, Patrick J ^a   Gibson, John ^al   Lonial, Sagar ^am   Krishnan, Amrita ^an   Dispenzieri, Angela ⁱ   Hari, Parameswaran ^c   more..

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h CENTER FOR CELL AND GENE THERAPY   (United States)

ⁱ MAYO CLINIC ROCHESTER   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^l City of Hope Samaritan BMT Program   (United States)

^m UNIVERSITY OF OTTAWA   (Canada)

ⁿ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^o UNIVERSITY OF FLORIDA   (United States)

^p VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^q IMPERIAL COLLEGE LONDON   (United Kingdom)

^r HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t KARMANOS CANCER INSTITUTE   (United States)

^u DANA FARBER CANCER INSTITUTE   (United States)

^v H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^w LERNER RESEARCH INSTITUTE   (United States)

^x NEBRASKA MEDICAL CENTER   (United States)

^y FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^z LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^aa MAYO CLINIC   (United States)

^ab ST LOUIS CHILDREN S HOSPITAL   (United States)

^ac NORTHSIDE HOSPITAL   (United States)

^ad UMASS MEMORIAL MEDICAL CENTER   (United States)

^ae ROYAL ADELAIDE HOSPITAL   (Australia)

^af FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^ag MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ah MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^ai OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^aj PHOENIX CHILDREN'S HOSPITAL   (United States)

^ak UNIVERSITY OF VIRGINIA   (United States)

^al ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^am EMORY UNIVERSITY HOSPITAL   (United States)

^an CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

Multiple myeloma; Relapsed multiple myeloma; Second autologous transplantation

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; DISEASE COURSE; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84876327529     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.004     Document Type: Article

References (31)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Moreau P., Avet-Loiseau H., Harousseau J.L., Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011, 29:1898-1906.
4. Koreth J., Cutler C.S., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007, 13:183-196.
5. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
6. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
7. Saad A.A., Sharma M., Higa G.M. Treatment of multiple myeloma in the targeted therapy era. Ann Pharmacother 2009, 43:329-338.
8. Kumar S.K., Lee J.H., Lahuerta J.J., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012, 26:149-157.
9. Burzynski J.A., Toro J.J., Patel R.C., et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymph 2009, 50:1442-1447.
10. Jimenez-Zepeda V.H., Mikhael J., Winter A., et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012, 18:773-779.
11. Mehta J., Tricot G., Jagannath S., et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant 1998, 21:887-892.
12. Olin R.L., Vogl D.T., Porter D.L., et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009, 43:417-422.
13. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006, 106:1084-1089.
14. Shah N., Ahmed F., Bashir Q., et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012, 118:3549-3555.
15. Fenk R., Liese V., Neubauer F., et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymph 2011, 52:1455-1462.
16. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
17. Anderson K.C., Alsina M., Bensinger W., et al. Multiple myeloma. JNCCN 2011, 9:1146-1183.
18. Larocca A., Palumbo A. Evolving paradigms in the treatment of newly diagnosed multiple myeloma. JNCCN 2011, 9:1186-1196.
19. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003, 349:2495-2502.
20. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007, 25:2434-2441.
21. Kumar A., Kharfan-Dabaja M.A., Glasmacher A., Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. JNCI 2009, 101:100-106.
22. Sonneveld P., van der Holt B., Segeren C.M., et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica 2007, 92:928-935.
23. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789-793.
24. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002, 99:731-735.
25. Morris C., Iacobelli S., Brand R., et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004, 22:1674-1681.
26. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1782-1791.
27. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1770-1781.
28. Riedel D.A., Pottern L.M. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992, 6:225-247.
29. Rastogi S, Johnson TD, Hoeffel EM, Drewery JMB. The Black Population: 2010. U.S. Census Bureau. Available at: 2010. http://wwwcensusgov/prod/cen2010/briefs/c2010br-06pdf.
30. Joshua T.V., Rizzo J.D., Zhang M.J., et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer 2010, 116:3469-3476.
31. Hari P.N., Majhail N.S., Zhang M.J., et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2010, 16:395-402.